Anavex Life Sciences Leadership Change
Anavex Life Sciences Corp. has appointed Terrie Kellmeyer, Ph.D., as its permanent President and Chief Executive Officer and as a member of the Board of Directors, effective November 1, 2026. Dr. Kellmeyer, who had been serving as Interim CEO since May 2026, will maintain an annual base salary of $500,000 with an anticipated 30% bonus. The appointment follows her leadership during a period of clinical program focus and increased engagement with the FDA.